Ratings by Credit Suisse (Trung Huynh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/8/2023 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/21/2023 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 6/29/2023 | Pfizer | PFE | Downgrade | Neutral (Outperform) |
36.42 (28.24) |
-22.46% | Details | |
| 5/5/2023 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 5/4/2023 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/3/2023 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/28/2023 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2023 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2023 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/1/2023 | Amgen | AMGN | Maintain | Underperform (N/A) |
|
Details | ||
| 1/31/2023 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/6/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2022 | Amgen | AMGN | New Coverage | Underperform (N/A) |
283.77 (442.36) |
55.89% | Details | |
| 11/18/2022 | Bristol-Myers Squibb Co. | BMY | New Coverage | Neutral (N/A) |
76.15 (67.61) |
-11.21% | Details | |
| 11/18/2022 | Johnson & Johnson | JNJ | New Coverage | Neutral (N/A) |
173.46 (273.41) |
57.62% | Details | |
| 11/18/2022 | Eli Lilly | LLY | New Coverage | Outperform (N/A) |
352.93 (1280.34) |
262.77% | Details | |
| 11/18/2022 | Pfizer | PFE | New Coverage | Outperform (N/A) |
48.05 (28.24) |
-41.23% | Details | |
| 11/18/2022 | Abbvie | ABBV | New Coverage | Outperform (N/A) |
151.87 (265.97) |
75.13% | Details | |
| 11/18/2022 | Merck | MRK | New Coverage | Outperform (N/A) |
99.93 (152.20) |
52.31% | Details | |
| 4/8/2021 | AstraZeneca | AZN | Maintain | Outperform (N/A) |
|
Details |
